Search
01/06/2026
Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.
Ferrer, L, Nadal, E, Dejean, T, Insa, A, Menu, P, Casal, J, Domine, M, Massuti, B, Majem, M, Martinez-Marti, A, Garcia-Campelo, R, Carpeño, JD, Cobo, M, Vivanco, GL, Morillo, ED, Bernabé, R, Vinolas, N, Barneto, I, Colin, T, Provencio, M. Cross-stage validation of a multimodal machine learning model to predict pathological complete response to neoadjuvant chemotherapy or chemoimmunotherapy in resectable stage III non-small cell lung cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8022. PMID:. IF:41.900(Q1/1D).
01/06/2026
Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain
Pacheco-Barcia, V, Obispo, B, Tomas, E, de Torres, CS, Quintanar, T, Paez, D, Leon-Mateos, L, Cancio, H, Cortegoso, A, Anido, U, Quilez, A, Tarazona, N, Jimenez-Labaig, P, Sanchez-Martinez, DA, Goni, AS, Fernandez-Montes, A, Felip, E, Rodriguez, C, Elez, E. Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain. Clinical & Translational Oncology. 2026; 28(6)DOI:10.1007/s12094-025-04171-x. PMID:41436708. IF:2.500(Q3/6D).
01/06/2026
First-in-human phase I study of CEB-01, a biodegradable SN-38-releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results
González-Lopez, J, Sebio, A, Broto, JM, Hindi, N, Villarejo-Campos, P, Jimenez, M, Díaz-Beveridge, R, Castellanos, JFO, Andajar, RL, Alvarez, RMA, Asencio, JM, Serrano, C, Conde, NR, Castro-Boix, S, Krauel, L, Colom, H, García, JAT, Lopera, E, Huguet, A, Campos, AP. First-in-human phase I study of CEB-01, a biodegradable SN-38-releasing membrane, to prevent local recurrence after resection of retroperitoneal sarcoma: Updated results. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23559. PMID:. IF:41.900(Q1/1D).
01/06/2026
Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019-2024).
Garrido, P, Villanueva, N, Bernabé, R, Campelo, RG, Sala, MA, Bote-de Cabo, H, Molla, MAI, Alvarez, R, Cruz, P, Majem, M, Santos, MAM, Cordero, MG, Rodriguez, JMO, Alvarez, RMA, Alvarez-Abril, B, Gutiérrez-Sainz, L, Gutiérrez, V, Munoz-Unceta, N, Felip, E, Isla, D. Sex-specific trends and outcomes in small cell lung cancer (SCLC) in Spain: Insights from the CLARISSE study (2019-2024).. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.8092. PMID:. IF:41.900(Q1/1D).
01/06/2026
Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.
Broto, JM, Terés, R, Marquina, G, Perez-Fidalgo, JA, Lopez-Jimenez, C, Alonso-Romero, JL, Redondo, A, Gutierrez, A, Casado, A, Sebio, A, Ledesma, P, Merino-Garcia, JA, Mayordomo, E, Moura, DS, Hindi, N. Phase I trial of LB-100 plus doxorubicin as first-line of advanced soft tissue sarcomas: A Spanish Sarcoma Group (GEIS) study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.11572. PMID:. IF:41.900(Q1/1D).
01/06/2026
Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial
Mondaza-Hernandez, JL, Moura, DS, Redondo, A, Sebio, A, Beveridge, RD, Martínez-Trufero, J, Romero-Gonzalez, P, Shirikova, A, Rodriguez, C, Carrera, M, Lopez-Jimenez, C, Hindi, N, Broto, JM. Plasma ISG15 as predictor of outcome from antiangiogenic therapy in solitary fibrous tumor: Analysis from the GEIS-69 trial. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(16_SUPPL)DOI:10.1200/JCO.2026.44.16_suppl.e23520. PMID:. IF:41.900(Q1/1D).